New Launch11 Dec 2025, 09:37 pm
Senores Pharmaceuticals Launches Deferiprone Tablets in US Market with Dr. Reddy's Laboratories
AI Summary
Senores Pharmaceuticals, a global research-driven pharmaceutical company, has announced the launch of Deferiprone Tablets USP, 500 mg & 1000 mg, in the U.S. market. The product, which is bioequivalent and therapeutically equivalent to Ferriprox Tablets of Chiesi USA, Inc., will be marketed by Dr. Reddy's Laboratories Inc. The company's strategic focus is on identifying and entering niche, under-penetrated generic formulations with an opportunity to serve unmet needs in healthcare. Deferiprone Tablets had U.S. sales of approximately $70 million MAT for the twelve months ending in October 2025 according to symphony.
Key Highlights
- Senores Pharmaceuticals launches Deferiprone Tablets USP, 500 mg & 1000 mg in the U.S. market.
- The product is bioequivalent and therapeutically equivalent to Ferriprox Tablets of Chiesi USA, Inc.
- The product will be marketed by Dr. Reddy's Laboratories Inc.
- The launch aligns with Senores' strategic focus on niche, under-penetrated generic formulations.
- Deferiprone Tablets had U.S. sales of approximately $70 million MAT for the twelve months ending in October 2025.